Which pre‑induction medicine causes less coughing: tegilidine or sufentanil

The Affiliated Lianyungang Hospital of Xuzhou Medical University

This will see if tegilidine or sufentanil causes less coughing when given before general anesthesia in adults having planned tracheal intubation.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 190 (estimated)
• Ages: 18 Years to 65 Years
• Sex: All
• Sponsor: The First People's Hospital of Lianyungang (other)
• Locations: 1 site (Lianyungang, Jiangsu)
• Trial ID: NCT07323043 on ClinicalTrials.gov

What this trial studies

This is a prospective, randomized, double‑blind, controlled comparison of tegilidine versus sufentanil given before induction of general anesthesia. Adult patients are randomly assigned to receive tegilidine (20–50 µg/kg) or sufentanil (0.4 µg/kg) after standard monitoring and preoxygenation, with no other drugs given beforehand. Cough is observed and graded two minutes after injection using a four‑grade scale based on frequency and duration. The study is single‑center and records the incidence and severity of cough during the induction period.

Who should consider this trial

Good fit: Adults aged 18–65 with BMI 18–30 kg/m2, ASA I–III, scheduled for elective surgery under general anesthesia with planned tracheal intubation are ideal candidates.

Not a fit: Patients with chronic cough or asthma, severe cardiovascular, intracranial, eye, or lung disease, or known allergy to the study drugs are excluded and are unlikely to benefit from participation.

Why it matters

Potential benefit: If successful, the results could identify a pre‑induction agent that reduces coughing during intubation, improving patient comfort and reducing airway or hemodynamic complications.

How similar studies have performed: Opioid‑induced cough (for example with fentanyl or sufentanil) has been documented and various mitigation strategies have been tested, but direct comparisons between tegilidine and sufentanil are limited.

Eligibility criteria

Inclusion Criteria:

1. Age between 18 and 65 years, 18 ≤ BMI (kg/m²) ≤ 30;
2. ASA grade I \~ III;
3. Scheduled elective surgery under general anesthesia with tracheal intubation.

Exclusion Criteria:

1. Patients with chronic cough (cough lasting \>8 weeks) or asthma;
2. Patients with a history of allergy to the drugs used during the study;
3. Patients with severe cardiovascular disease, intracranial lesions, eye lesions, or lung lesions.

Where this trial is running

Lianyungang, Jiangsu

• The Affiliated Lianyungang Hospital of Xuzhou Medical University — Lianyungang, Jiangsu, China (RECRUITING)

Study contacts

• Study coordinator: Xiaobao Zhang, Doctor

Conditions: General Anesthetic Drug Adverse Reaction